Novo Nordisk (NOV) Price & Analysis

Compare

585 Followers

NOV Stock Chart & Stats

€44.42

€0.79(0.95%)

At close: Jan 09 4:00 PM EST

€44.42

€0.79(0.95%)

Day’s Range― - ―

52-Week Range€35.76 - €104.78

Previous CloseN/A

Volume21.06K

Average Volume (3M)333.55K

Market Cap

€197.03B

Enterprise Value€2.04T

Total Cash (Recent Filing)€41.55B

Total Debt (Recent Filing)€118.72B

Price to Earnings (P/E)14.2

Beta0.88

Next Earnings

Feb 04, 2026

EPS Estimate

0.79

Next Dividend Ex-DateN/A

Dividend Yield3.47%

Share Statistics

EPS (TTM)0.60

Shares Outstanding3,390,128,000

10 Day Avg. Volume247,790

30 Day Avg. Volume333,550

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)0.00

Price to Sales (P/S)0.00

P/FCF Ratio0.00

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

€50.23

Price Target Upside13.08% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering12

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Clinical TrialsNovo Nordisk's trial for Rybelsus in Alzheimer's could be clinically meaningful even with modest benefits, thanks to its broad safety profile.

Product StrategyNovo Nordisk is proactively engaging with physicians to optimize dosing strategies, which could enhance the safety and tolerability profile of its products.

Regulatory ProgressNovo Nordisk confirmed the filing of the Semaglutide 7.2mg dose in the US, indicating regulatory progress.

Bears Say

Financial GuidanceNovo announced an EBIT guide cut on restructuring costs, with the guide range lowered significantly, making the net benefit unclear.

Growth ExpectationsThe company is not viewed as a 'premium' growth entity anymore, with debates expected around the trading price-to-earnings multiple into the future.

Prescription TrendsThere is a lack of growth in prescription trends for Wegovy and Ozempic, with market pressure anticipated from patent expiry and competitor launches.

Novo Nordisk News

Mixed options sentiment in Novo Nordisk with shares up 1.79%

Mixed options sentiment in Novo Nordisk (NVO), with shares up 92c, or 1.79%, near $52.53. Options volume running...

2d ago

NVO

Unusually active option classes on open December 24th

Unusual total active option classes on open include: Forrester (FORR), Nike (NKE), AST SpaceMobile (ASTS), Zeta Global Holdings...

2d ago

NKE

NVO

Novo, Lilly race to cement lead in India’s obesity drug market, Reuters says

Eli Lilly (LLY) and Novo Nordisk (NVO) are racing to cement their lead in India’s obesity drug market...

2d ago

LLY

NVO

KeyBanc sees West, Stevanato ramping despite oral Wegovy approval

KeyBanc believes the risk to oral weight loss drugs remains limited to 2030 from the approval of Wegovy’s...

2d ago

NVO

WST

Midday Fly By: Wegovy weight loss pill approved, ServiceNow inks security deal

Fed rate cut bets have been pared by traders after the blowout GDP report that showed higher-than-expected growth...

3d ago

AME

Novo Nordisk rises 8.1%

Novo Nordisk (NVO) is up 8.1%, or $3.92 to $52.02. Published first on TheFly – the ultimate source...

3d ago

NVO

Novo Nordisk rises 9.0%

Novo Nordisk (NVO) is up 9.0%, or $4.34 to $52.44. Published first on TheFly – the ultimate source...

3d ago

NVO

Unusually active option classes on open December 23rd

Unusual total active option classes on open include: Rezolve AI Ltd (RZLV), Novo Nordisk (NVO), PepsiCo (PEP), Kinder...

3d ago

DJT

KMI

Morning Movers: Novo Nordisk gains after Wegovy pill approved

Stock futures edged lower after delayed economic data arrived far stronger than expected. The U.S. economy posted robust...

3d ago

HII

JNJ

Video: HII sails higher as President unveils plans for ‘Trump-class’ battleships

The Fly has brought its to-the-moment stock market reporting to YouTube! Subscribe if you want to know how...

3d ago

HII

NVO

Novo Nordisk: Oral Wegovy Approval Restores Momentum but Competitive Pressures Justify Hold Rating

BMO Capital analyst Edwin Chee has maintained their neutral stance on NVO stock, giving a Hold rating on...

3d ago

NVO

Evan Seigerman Issues Hold Rating for Novo Nordisk Amid Revenue Decline Concerns and Market Challenges

Evan Seigerman, an analyst from BMO Capital, maintained the Hold rating on Novo Nordisk. The associated price target...

1M ago

NVO

Novo Nordisk Faces Challenges Amid Intensifying Competition and Market Pressures

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk today and set a price target...

2M ago

NVO

Cautious Hold Rating on Novo Nordisk Amid Competitive Pressures and Uncertain Growth Prospects

Analyst Evan Seigerman of BMO Capital reiterated a Hold rating on Novo Nordisk, boosting the price target to...

2M ago

NVO

NOV FAQ

What was Novo Nordisk’s price range in the past 12 months?

Novo Nordisk lowest stock price was €35.76 and its highest was €104.78 in the past 12 months.

What is Novo Nordisk’s market cap?

Novo Nordisk’s market cap is €197.03B.

When is Novo Nordisk’s upcoming earnings report date?

Novo Nordisk’s upcoming earnings report date is Feb 04, 2026 which is in 40 days.

How were Novo Nordisk’s earnings last quarter?

Novo Nordisk released its earnings results on Nov 05, 2025. The company reported €0.602 earnings per share for the quarter, missing the consensus estimate of €0.655 by -€0.053.

Is Novo Nordisk overvalued?

According to Wall Street analysts Novo Nordisk’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Novo Nordisk pay dividends?

Novo Nordisk pays a Semiannually dividend of €0.502 which represents an annual dividend yield of 3.47%. See more information on Novo Nordisk dividends here

What is Novo Nordisk’s EPS estimate?

Novo Nordisk’s EPS estimate is 0.79.

How many shares outstanding does Novo Nordisk have?

Novo Nordisk has 3,390,128,000 shares outstanding.

What happened to Novo Nordisk’s price movement after its last earnings report?

Novo Nordisk reported an EPS of €0.602 in its last earnings report, missing expectations of €0.655. Following the earnings report the stock price went down -4.225%.

Which hedge fund is a major shareholder of Novo Nordisk?

Currently, no hedge funds are holding shares in DE:NOV

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Novo Nordisk

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Rare Disease. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, glucagon, needles, and other chronic diseases. The Rare Disease segment offers products in the areas of haemophilia, blood disorders, endocrine disorders, growth disorders, and hormone replacement therapy. The company has a collaboration agreement with Gilead Sciences, Inc.; and research collaboration with Novo Nordisk to discover cell-specific carriers of nucleic acid therapeutics. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Novo Nordisk (NOV) Earnings & Revenues

Historic Earnings Reports

NOV Stock 12 Month Forecast

Average Price Target

€50.23

▲(13.08% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"35":"€35","68":"€68","101":"€101","51.5":"€51.5","84.5":"€84.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":72.29358,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€72.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":50.22797286,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€50.23</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":36.14679,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€36.15</span>\n  </div></div>","useHTML":true}}],"tickPositions":[35,51.5,68,84.5,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Mar<br/>2025","6":"Jun<br/>2025","9":"Sep<br/>2025","12":"Dec<br/>2025","25":"Dec<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.14,44.45950615384616,46.77901230769231,49.09851846153846,51.41802461538462,53.73753076923077,56.05703692307692,58.37654307692308,60.69604923076923,63.01555538461539,65.33506153846155,67.6545676923077,69.97407384615386,{"y":72.29358,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.14,42.76215175846154,43.384303516923076,44.00645527538462,44.62860703384615,45.25075879230769,45.872910550769234,46.49506230923077,47.11721406769231,47.73936582615384,48.361517584615385,48.983669343076926,49.60582110153846,{"y":50.22797286,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,42.14,41.67898384615385,41.217967692307695,40.75695153846154,40.29593538461538,39.83491923076923,39.37390307692308,38.912886923076925,38.45187076923077,37.99085461538462,37.52983846153846,37.06882230769231,36.607806153846155,{"y":36.14679,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":100.837,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 8</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":81.418,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":79.367,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.034,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 30,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.389,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":57.666,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.667,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":58.842,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.168,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48.92,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":50.07,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 24, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.58,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":42.14,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 17, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >